Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase II Study BMS-986278, a potential first-in-class oral l...
Over the past several years, multiple myeloma treatment options have expanded widely for patients, resulting in significantly improved outcomes. The FDA approved around 16 new agents and 30 treatment regimens, transforming the multiple myeloma treatment paradigm for patients with newly diagnosed and relapsed/refrac...
Find MoreLung cancer remains the leading cause of cancer-related death in the United States. The American Cancer Society estimates 238,340 people will be diagnosed with lung cancer in 2023, with non-small cell lung cancer (NSCLC) accounting for the majority of cases (roughly 80% to 85%).The treatment paradigm of antibody-dr...
Find MoreChronic pain is an unwelcome companion in the journey of life and can significantly impact the quality of life. Being in pain serves as a protective mechanism that warns us when something is wrong with the concerned body part, and is a natural component of the human experience. But for millions of people around the...
Find MoreFDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy Designations (BTDs) in the United States for the treatment of adult patients with unresectable or metastati...
Find MoreThe landscape of multiple myeloma treatment has undergone a profound transformation with the advent of monoclonal antibodies (mAbs) targeting CD38. Among the notable breakthroughs, two anti-CD38 mAbs, DARZALEX (daratumumab) and SARCLISA (isatuximab-irfc), have been approved for clinical use. These groundbreaking mu...
Find MoreGE HealthCare Launched CardioVisio for Atrial Fibrillation, a Digital, Patient-Centric Clinical Decision Support Tool to Enable Precision Care On August 24, 2023, GE HealthCare launched CardioVisio for Atrial Fibrillation (AFib), a digital tool designed to assist clinicians in visualizing longitudinal data relev...
Find MoreFDA Approves Bristol Myers Squibb’s Reblozyl as First-Line Treatment of Anemia in Adults with Lower-Risk MDS Who May Require Transfusions Bristol Myers Squibb announced that the Food and Drug Administration (FDA) has approved Reblozyl® (luspatercept-aamt) for the treatment of anemia in adult patients with very l...
Find MoreStep aside, CAR-Ts; with three FDA approvals, the class of bispecific antibodies has begun to take on the relapsed/refractory multiple myeloma treatment segment. Currently, the US Food and Drug Administration (FDA) has authorized 10 bispecific antibodies and one bispecific molecule, the majority of which are a...
Find MoreSmith+Nephew Launched Hip Arthroplasty System in India On August 17, 2023, The London-based orthopedic device maker Smith+Nephew announced the launch of its OR3O dual mobility system for use in primary and revision hip arthroplasty in India. The dual mobility implants have a smaller-diameter femoral hea...
Find MoreMajor Depressive Disorder (MDD), also known as clinical depression, is a severe, debilitating and fr.....
Find MoreGene Therapy has shown tremendous growth in the past few years. The use of AAV (adeno-associated vir.....
Find MoreIPSCs have enormous applications in the field of regenerative medicine, disease modelling, and drug .....
Find MoreLyme disease is a vector-borne infectious disease that spreads primarily by the bite of a tick (also.....
Find MoreCocaine Use Disorder (CUD) is characterized as a substance use disorder in which biological, psychol.....
Find MoreAge-related macular degeneration (AMD) is an eye disease, which may obscure the simple, central use .....
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.